The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety

Journal of Psychiatric Research

Volumn 33, Issue 3, 1999, Pages 181-214

  Holsboer, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CANNABINOID; COCAINE; CORTICOSTEROID RECEPTOR; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MESSENGER RNA; MOCLOBEMIDE; PYRIMIDINE DERIVATIVE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ANXIETY; BRAIN; CLINICAL TRIAL; DEPRESSION; GENE DELETION; GENETIC RISK; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; STRESS; TRANSGENIC MOUSE;

EID: 0032895726     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(98)90056-5     Document Type: Review

References (229)

1. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 1994;15:321-50.
2. Aldenhoff JB, Gruol DL, Rivier J, Vale W, Siggins GR. Corticotrophin-releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. Science 1983;221:875-7.
3. Antoni F. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue CRF. Endocrine Rev 1986;7:351-8.
4. Arato M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRH in suicide victims. Biol Psychiatry 1989;25:355-9.
5. Baldwin HA, Rassnick S, Koob GF, Britton KT. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology 1991;103:227-32.
6. Banki CM, Bissette G, Arato M, O'Conner L, Nemeroff CB. Cerebrospinal fluid corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987;144:873-7.
7. Baram TZ, Hirsch E, Snead OC 3rd, Schultz L. Corticotropin-releasing hormone-induced seizures in infant rats originate in the amygdala. Ann Neurol 1992;31:488-94.
8. Baram TZ, Mitchell WG, Haden E. Inhibition of pituitary-adrenal secretion by a corticotropin releasing hormone antagonist in humans. Mol Psychiatry 1996a;1:320-4.
9. Baram TZ, Koutsoukos Y, Schultz L, Rivier J. The effect of 'Astressin', a novel antagonist of corticotropin releasing hormone (CRH), on CRH-induced seizures in the infant rat: comparison with two other antagonists. Mol Psychiatry 1996b;1:223-6.
10. Baram TZ, Chalmers DT, Chen C, Koutsoukos Y, de Souza EB. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res 1997;770:89-95.
11. Barden N, Stec ISM, Montkowski A, Holsboer F, Reul JMHM. Endocrine profile and neuroendocrine challenge test in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 1997;66:212-20.
12. Behan DP, Heinrichs SC, Troncoso JC, Liu X-J, Kawas CH, Ling N, de Souza EB. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature 1995a;378:284-7.
13. Behan DP, Maciejewski D, Chalmers D, de Souza EB. Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells. Brain Res 1995b;698:259-64.
14. Behan DP, Khongsaly O, Owens MJ, Chung HD, Nemeroff CB, de Souza EB. Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer's disease and control postmortem human brain. J Neurochem 1997;68:2053-60.
15. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog NeuroBiol 1998;56:1-23.
16. Bissette G, Reynolds GP, Kilts CD, Widerlov W, Nemeroff CB. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. JAMA 1985;254:3067-9.
17. Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-9.
18. Bourgeois S, Gruol DJ, Newby RF, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 1993;7:840-51.
19. Bradbury M, Akana SF, Dallman MF. Roles of type 1 and type 2 corticosteroid receptors in the regulation of basal activity in the hypothalamic-pituitary-adrenal axis during the diurnal trough and peak: evidence for a non-additive effect of combined receptor occupation. Endocrinology 1994;134:1286-96.
20. Britton DR, Koob GF, River H, Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 1982;31:363-7.
21. Britton KT, Lee G, Vale W, Rivier J, Koob GF. Corticotropin-releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Res 1986;369:303-6.
22. Butler PD, Weiss JM, Stout JC, Nemeroff CB. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci 1990;10:176-83.
23. 2+ levels in neuronal culture. Eur J Pharmacol 1992;219:53-7.
24. Caldji C, Tannenbaum B, Sharma S, Francis D, Plotsky PM, Meaney MJ. Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc Natl Acad Sci USA 1998;95:5335-40.
25. Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression. J Neurosci 1995;15:6340-50.
26. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 1996;17:166-72.
27. Chang CP, Pearse RV 2nd, O'Connell S, Rosenfeld MG. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993;11:1187-95.
28. Charlton BG, Cheetham SC, Horton RW, Katona CLE, Crompton MR, Ferrier IN. Corticotropin-releasing factor immunoreactivity in post-mortem brain from depressed suicides. J Psychopharmacol 1988;2:13-8.
29. Chen C, Dagnino R, De Souza EB, Grigoriadis DE, Huang CQ, Kim K-I, Liu T, Moran T, Webb TR, Witten JP, Xie YF, McCarthy JR. Design and synthesis of a series of non-peptide high affinity human corticotropin releasing factor-1 receptor antagonists. J Med Chem 1996;39:4358-60.
30. Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing factor receptor. Proc Natl Acad Sci USA 1993;90:8967-71.
31. Choi JJ, Huang G-J, Shafik E, Wu W-H, McArdle JJ. Imipramine's selective suppression of an L-type calcium channel in neurons of murine dorsal root ganglia involves G proteins. J Pharmacol Exp Ther 1992;263:49-53.
32. Collins S, Caron MG, Lefkowitz RJ. β2-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol Chem 1988;263:9067-70.
33. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult non-human primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci USA 1996;93:1619-23.
34. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
35. Costa A, Yasin SA, Hucks D, Forsling ML, Besser GM, Grossman A. Differential effects of neuroexcitatory amino acids on corticotropin-releasing hormone-41 and vasopressin release from rat hypothalamic explants. Endocrinology 1992;131:2595-602.
36. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-95.
37. Dallman MF. Stress Update. Adaptation of the hypothalamic-pituitary-adrenal axis to chronic stress. Trends Endocrinol Metab 1993;4:62-9.
38. Dautzenberg FM, Dietrich K, Palchaudhuri MR, Spiess J. Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor. J Neurochem 1997;69:1640-9.
39. Dautzenberg FM, Wille S, Lohmann R, Spiess J Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: Implications for the ligand-binding site. Proc Natl Acad Sci USA 1998;95:4941-6.
40. Day JC, Koehl M, Deroche V, Le Moal M, Stefania M. Prenatal stress enhances stress- and corticotropin-releasing factor-induced stimulation of hippocampal acetylcholine release in adult rats. J Neurosci 1998;18:1886-92.
41. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993;150:656-7.
42. De Goeij DC, Kvetnansky R, Whitnall MH, Jezova D, Berkenbosch F, Tilders FJ. Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. Neuroendocrinology 1991;53:150-9.
43. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocrine Rev 1998;19:269-301.
44. De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 1986;319:593-5.
45. Dijkstra I, Tilders FJH, Aguilera G, Kiss A, Rabadan-Diehl C, Barden N, Karanth S, Holsboer F, Reul JMHM. Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucocorticoid receptor function. J Neurosci 1998;18:3009-918.
46. Drouin J, Maira M, Philips A. Novel mechanism of action for Nur77 and antagonism by glucocorticoids: a convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription. J Steroid Biochem Mol Biol 1998;65:59-63.
47. Duman RS, Nestler EJ. Signal transduction pathways for catecholamine receptors. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress, New York, Raven Press, 1995:303-20.
48. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
49. Dunn AJ, File SE. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Hormones Behav 1987;21:193-202.
50. Dunn AJ, Berridge CW. Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71-100.
51. Ehlers CL, Reed TK, Henriksen SJ. Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. Neuroendocrinology 1986;42:467-74.
52. Gallagher M, Chiba AA. The amygdala and emotion. Curr Opin Neurobiol 1996;6:221-7.
53. Geracioti TD Jr, Orth DN, Ekhator NN, Blumenkopf B, Loosen PT. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992;74:1325-30.
54. Geracioti TD Jr, Loosen PT, Orth DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997;42:166-74.
55. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, Schulte H, Oldfield E, Loriaux DI. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984;141:619-27.
56. Griebel G, Perrault G, Sanger DJ. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 1998;138:55-66.
57. Hauger RL, Aguilera G. Regulation of pituitary corticotropin-releasing hormone receptors by CRH: interaction with vasopressin. Endocrinology 1993;133:1708-14.
58. Hauger RL, Irwin MR, Lorang M, Aguilera G, Brown MR. High intracerebral levels of CRH result in CRH receptor downregulation in the amygdala and neuroimmune desensitization. Brain Res 1993;616:283-92.
59. Hauger RL, Dautzenberg FM, Flaccus A, Liepold T, Spiess J. Regulation of corticotropin-releasing factor receptor function in human Y-79 retinoblastoma cells: rapid and reversible homologous desensitization but prolonged recovery. J Neurochem 1997;68:2308-16.
60. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, Cato AC. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 1994;13:4087-95.
61. Heinrichs SC, Merlo-Pich E, Miczeck KA, Britton KT, Koob GF. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 1992;581:190-7.
62. Heinrichs SC, Menzaghi F, Merlo-Pich E, Baldwin HA, Rassnick S, Britton KT, Koob GF. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 1994;11:179-86.
63. Heinrichs SC, Stenzel-Poore MP, Gold LH, Battenberg E, Bloom FE, Koob GF, Vale WW, Merlo-Pich E. Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor. Neuroscience 1996;74:303-11.
64. 2, receptors mediate anxiogenic-like behavior. Regul Peptides 1997;71:15-21.
65. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatric Res 1994;28:341-56.
66. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and in normal comparison subjects. Am J Psychiatry 1996;153:93-9.
67. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 1998; in press.
68. Holsboer F. Prediction of clinical course by dexamethasone suppression test (DST) response in depressed patients - physiological and clinical construct validity of the DST. Pharmacopsychiatry 1983;16:186-91.
69. Holsboer F. Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995a:957-69.
70. Holsboer F, Barden N. Antidepressants and HPA regulation. Endocrine Rev 1996;17:187-205.
71. Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Müller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984a;311:1127.
72. Holsboer F, Müller OA, Doerr HG, Sippell WG, Stalla GK, Gerken A, Steiger A, Boll E, Benkert O. ACTH and multisteroid responses to corticotropin-releasing factor in depressive illness: relationship to multisteroid responses after ACTH stimulation and dexamethasone suppression. Psychoneuroendocrinology 1984b;9:147-69.
73. Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Müller OA, Stalla GK. Human corticotropin-releasing hormone in depression. Biol Psychiatry 1986;21:601-11.
74. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Hormone Metab Res 1987a;19:80-8.
75. Holsboer F, von Bardeleben U, Wiedemann K, Müller OA, Stalla GK. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression - Implications for pathophysiology of DST nonsuppression. Biol Psychiatry 1987b;22:228-34.
76. Holsboer F, von Bardeleben U, Steiger A. Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology 1988;48:32-8.
77. Holsboer F, Spengler D, Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushings's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992;93:385-417.
78. Holsboer F, Lauer CJ, Schreiber W, Krieg J-C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995b;62:340-7.
79. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - neurobiological and psychometric assessment of course. J Psychiatric Res 1994;28:381-99.
80. Hsu DT, Chen F-L, Takahashi LK, Kalin NH. Rapid stress-induced elevations in corticotropin-releasing hormone mRNA in rat central amygdala nucleus and hypothalamic paraventricular nucleus: An in situ hybridization analysis. Brain Res 1998;788:305-10.
81. Hucks D, Lowther S, Crompton MR, Katona CLE, Horton RW. Corticotropin-releasing factor binding sites in cortex of depressed suicides. Psychopharmacology 1997;134:174-8.
82. Imaki T, Vale W. Chlordiazepoxide attenuates stress-induced accumulation of corticotropin-releasing factor mRNA in the paraventricular nucleus. Brain Res 1993;623:223-8.
83. 1 receptor expression by stress and agonist treatments in brain and cultured cells. Mol Pharmacol 1996;50:1103-10.
84. Iredale PA, Bundey R, Duman RS. Phorbol ester and calcium regulation of corticotropin-releasing factor receptor 1 expression in a neuronal cell line. J Neurochem 1997;69:1912-19.
85. Jezova D, Oprsalova Z. Adrenocorticotropin release induced by N-methyl-D-aspartate or stress: mediation by the area postrema. J Neuroendocrinol 1992;4:145-7.
86. Joanny P, Steinberg J, Oliver C, Grino M. Glutamate and N-methyl-D-aspartate stimulate rat hypothalamic corticotropin-releasing factor secretion in vitro. J Neuroendocrinol 1997;9:93-7.
87. Joshi J, Sabol SL. Proenkephalin gene expression in C6 rat glioma cells: potentiation of cyclic adenosine 3′,5′-monophosphate-dependent transcription by glucocorticoids. Mol Endocrinol 1991;5:1069-80.
88. Kalin NH. Behavioral and endocrine studies of corticotropin-releasing hormone in primates. In: De Souza EB, Nemeroff CB, editors. Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide. Boca Raton: CRC Press. 1990:275-89.
89. Kendler KS. Major depression and the environment: a psychiatric genetic perspective. Pharmacopsychiatry 1998;31:5-9.
90. Kendler KS, Karkowski-Shuman L. Stressful life events and genetic liability to major depression: genetic control of exposure to the environment? Psychol Med 1997;27:539-47.
91. Koob GF, Bloom FE. Corticotropin-releasing factor and behavior. Fed Proc 1985;44:259-63.
92. Koob GF, Heinrichs SC, Merlo-Pich E, Menzaghi F, Baldwin H, Miczek H, Britton KT. The role of corticotropin-releasing factor in behavioural response to stress. In: De Souza EB, Nemeroff CB, editors. Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide. Boca Raton: CRC Press. 1993:277-95.
93. Koob GF, Heinrichs SC, Menzaghi F, Pich EM, Britton KT. Corticotropin-releasing factor, stress and behavior. Semin Neurosci 1994;6:221-9.
94. Korte, SM, Korte-Bouws GAH, Bohus B, Koob GF. Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats. Physiol Behav 1994;56:115-20.
95. 2γ receptor. Mol Endocrinol 1998;12:1077-85.
96. Kupfer DJ. Management of recurrent depression. J Clin Psychiatry 1993;54 Suppl 2:29-33.
97. LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 1998;20:937-45.
98. Ladd CO, Owens MJ, Nemeroff CB. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 1996;137:1212-18.
99. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F, Engelmann M. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities and anxiety-related behavior in rats. J Neurosci 1995;15:4250-58.
100. Lauer CJ, Schreiber W, Modell S, Holsboer F, Krieg J-C. The Munich vulnerability study on affective disorders: overview of the cross-sectional observations at index investigation. J Psychiatric Res 1998;32:393-401.
101. Leake A, Perry EK, Perry RH, Fairbairn AF, Ferrier IN. Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression. Biol Psychiatry 1990;28:603-8.
102. Lefkowitz RJ. G protein-coupled receptor kinase. Cell 1993;74:409-12.
103. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Peptides 1995;59:229-39.
104. Liebsch G, Montkowski A, Holsboer F, Landgraf R. Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res 1998;94:301-10.
105. 2 receptor antisense oligonucleotides into the rat brain. J Psychiatric Res 1999;33:153-163.
106. Linthorst ACE, Flachskamm C, Hopkins SJ, Hoadley ME, Labeur MS, Holsboer F, Reul JMHM. Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomie, behavioral, and cytokine responses to a systemic inflammatory challenge. J Neurosci 1997;17:4448-60.
107. Lisansky J, Peake GT, Strassman RJ, Qualls C, Meikle AW, Risch SC, Fava GA, Zownir-Brazis M, Hochla P, Britton D. Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pre-treated with metyrapone. Arch Gen Psychiatry 1989;46:641-9.
108. Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman A, Sharma S, Pearson D, Plotsky PM, Meaney MJ. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 1997;277:1659-62.
109. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92:836-40.
110. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau JL. A non-peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 1996;309:195-200.
111. Luo X, Kiss A, Makara G, Lolait SJ, Aguilera G. Stress-specific regulation of corticotropin releasing hormone receptor expression in the paraventricular and supraoptic nuclei of the hypothalamus in the rat. J Neuroendocrinol 1994;6:689-96.
112. Malkoski SP, Handanos CM, Dorin RI. Localization of a negative glucocorticoid response element of the human corticotropin releasing hormone gene. Mol Cell Endocrinol 1997;127:189-99.
113. 1 receptor antagonist. Eur J Pharmacol 1997;323:21-6.
114. Meeker RB, Greenwood RS, Hayward JN. Glutamate receptors in the rat hypothalamus and pituitary. Endocrinology 1994;134:621-9.
115. Meijer OC, de Lange ECM, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998;139:1789-93.
116. Melia KR, Duman RS. Involvement of corticotropin-releasing factor in chronic stress regulation of the brain noradrenergic system. Proc Natl Acad Sci U.S.A. 1991;88:8382-6.
117. Menzaghi F, Howard RL, Heinrichs SC, Valer W, Rivier J, Koob GF. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 1994;269:564-72.
118. Merchenthaler J Corticotropin-releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 1994;5:53-69.
119. Meyer TE, Habener JF. Cyclic adenosine 3′,5′-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocrine Rev 1993;14:269-90.
120. Michelson D, Galliven E, Hill L, Demitrack M, Chrousos G, Gold P. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997;82:2601-6.
121. Mobley PL, Sulser F. Adrenal corticoids regulate sensitivity of noradrenaline receptor-coupled adenylate cyclase in brain. Nature 1980;286:608-9.
122. Modell S, Yassouridis A, Huber J, Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997;65:216-22.
123. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg J-C, Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 1998;18:253-62.
124. Molchan SE, Hill JL, Martinez RA, Lawlor BA, Mellow AM, Rubinow DR, Bissette G, Nemeroff CB, Sunderland T. CSF somatostatin in Alzheimer's disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 1993;18:509-19.
125. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JMHM, Landgraf R, Holsboer F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 1995;7:841-5.
126. Moreau JI, Kilpatrick G, Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport 1997;8:1697-1701.
127. Mori S, Zanardi R, Popoli M, Garbini S, Brunello N, Smeraldi E, Racagni G, Perez J. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide. J Psychiatric Res 1998;32:111-5.
128. Murphy BEP. Steroids and depression. J Steroid Biochem Mol Biol 1991;38:537-59.
129. Murphy BEP and Conneely OM. Neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. Mol Endocrinol 1997;11:39-47.
130. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts DC, Loosen PT, Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-4.
131. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577-9.
132. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989;53:1644-7.
133. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-72.
134. Orth DN. Corticotropin-releasing hormone in humans. Endocrine Rev 1992;13:164-91.
135. Owens MJ, Nemeroff CB. The physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1992;43:425-73.
136. Owens MJ, Bissette G, Nemeroff CB. Acute effects of alprazolam and adimazolam on the concentration of corticotropin-releasing factor in the rat brain. Synapse 1989;4:196-202.
137. Parkes D, Rivest S, Lee S, Rivier C, Vale W. Corticotropin-releasing factor activates c-fos, NGFI-B, and corticotropin-releasing factor gene expression within the paraventricular nucleus of the rat hypothalamus. Mol Endocrinol 1993;7:1357-67.
138. Patchev VK, Shoaib M, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone counteracts CRH-induced anxiety and alters the release and gene expression of CRH in the rat hypothalamus. Neuroscience 1994a;62:265-71.
139. Patchev VK, Karalis K, Chrousos GP. Effects of excitatory amino acid transmitters on hypothalamic corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP) release in vitro: implications in pituitary-adrenal regulation. Brain Res 1994b;633:312-6.
140. Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almeida OFX. Neonatal treatment of rats with the neurosteroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest 1997;99:962-6.
141. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-22.
142. Pepin MC, Beaulieu S, Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol Brain Res 1989;6:77-83.
143. Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992;355:725-8.
144. Perez J, Tinelli D, Brunello N, Racagni G. cAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol 1989;172:305-16.
145. Perez J, Tinelli D, Bianchi E, Brunello N, Racagni G. cAMP binding proteins in the rat cerebral cortex after administration of selective 5-HT and NE reuptake blockers with antidepressant activity. Neuropsychopharmacology 1991:4:57-64.
146. Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 1993;133:3058-61.
147. Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 1995;92:2969-73.
148. Phi Van L, Spengler D, Holsboer F. Glucocorticoid repression of cAMP-dependent hCRH gene promoter activity in a transfected mouse anterior pituitary cell line. Endocrinology 1990;127:1412-8.
149. Pitts AF, Samuelson SD, Meller WH, Bissette G, Nemeroff CB, Kathos RG. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol Psychiatry 1995;38:330-5.
150. Plotsky PM. Noli disturbare circulos meos: Integrative role for CRF in organization of the stress response. In: Nappi G, et al. editors. Stress and the Aging Brain. New York: Raven Press, 1990.
151. Pomara N, Singh RR, Deptula D, Lewitt PA, Bissette G, Stanley M, Nemeroff CB. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites. Biol Psychiatry 1989;26:500-4.
152. Potter E, Behan DP, Fischer WH, Linton EA, Lowry PJ, Vale WW. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 1991;349:423-6.
153. Potter E, Behan DP, Liton EA, Lowry PJ, Sawchenko PE, Vale WW. The central distribution of a corticotropin-releasing factor(CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc Natl Acad Sci USA 1992;89:4192-6.
154. Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, Vale W. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA 1994;91:8777-81.
155. Price ML, Curtis AL, Kirby LG, Valentino RJ, Lucki I. Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 1998;18:492-502.
156. Purba JS, Hoogendijk WJG, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137-43.
157. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994:60:433-6.
158. Rabadan-Diehl C, Makara G, Kiss A, Zelena D, Aguilera G. Regulation of pituitary corticotropin-releasing hormone (CRH) receptor mRNA and CRH binding during adrenalectomy: role of glucocorticoids and hypothalamic factors. J Neuroendocrinol 1997;9:689-97.
159. Racagni G. Brunello N, Tinelli D, Perez J. New biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry 1992;25:51-5.
160. Rainnie DG, Fernhout BJ, Shinnick-Gallagher P. Differential actions of
161. Rangarajan PN, Umesono K, Evans RM. Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol 1992;6:1451-7.
162. Rassnick S, Heinrichs SC, Britton KT, Koob GF. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 1993;605:25-32.
163. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41.
164. Reul JMHM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993;133:312-20.
165. Reul JMHM, Stec I, Wiegers GJ, Labeur MS, Linthorst ACE, Arzt E, Holsboer F. Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats. J Clin Invest 1994a;93:2600-7.
166. Reul JMHM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994b;60:509-19.
167. Reyes A, Luckhaus J, Ferin M. Unexpected inhibitory action of N-methyl-D,L-aspartate on luteinizing hormone release in adult ovariectomized rhesus monkeys: a role of the hypothalamic-adrenal axis. Endocrinology 1990;127:724-9.
168. Richards JG, Schoch P, Haring P, Takacs B, Möhler H. Resolving GABAA/benzodiazepine receptors: cellular and subcellular localization in the CNS with monoclonal antibodies. J Neurosci 1987;7:1866-86.
169. Rivest S, Laflamme N, Nappi RE. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J Neurosci 1995;15:2680-95.
170. Rivier J, Rivier C, Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect of ACTH secretion in the rat. Science 1984;224:889-91.
171. 37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996;276:56-64.
172. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997;276:2050-4.
173. Roe SY, McGowan EM, Rothwell NJ. Evidence for the involvement of corticotropin-releasing hormone in the pathogenesis of traumatic brain injury. Eur J Neurosci 1998;10:553-9.
174. Rowe W, Steverman A, Walker M, Sharma S, Barden N, Seckl JR, Meaney MJ. Antidepressants restore hypothalamic-pituitary-adrenal feedback function in aged, cognitively-impaired rats. NeuroBiol Aging 1997;18:527-33.
175. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 1986;143:896-9.
176. Rueter LE, Jacobs BL. A microdialysis examination of serotonin release in the rat forebrain induced by behavioral/environmental manipulations. Brain Res 1996;739:57-69.
177. Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids: Cellular and systemic effects. J Psychiatric Res 1997;31:297-314.
178. Sakaue M, Saito N, Taniguchi H, Baba S, Tanaka C. Immunohistochemical localization of γ-aminobutyric acid in the rat pituitary gland and related hypothalamic regions. Brain Res 1988;446:343-53.
179. Schinkel AH, Wagenaar E, Van Deemter L, Mol CAAM, Borst P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705.
180. Schüle R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma IM, Evans RM. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990;62:1217-26.
181. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD 3rd, Winston EN, Chen YL, Heym J. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 1996;93:10477-82.
182. Seasholtz AF, Thompson RC, Douglass JO. Identification of a cyclic adenosine monophosphate-responsive element in the rat corticotropin-releasing hormone gene. Mol Endocrinol 1988;2:1311-9.
183. 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology 1998;137:184-90.
184. Sheng M, McFadden G, Greenberg ME. Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron 1990;4:571-82.
185. Sherman JE, Kalin NH. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol Biochem Behav 1988;30:801-7.
186. Singh VB, Hao-Phan T, Corley KC, Boadle-Biber MC. Increase in cortical and midbrain tryptophan hydroxylase activity by intracerebroventricular administration of corticotropin-releasing factor. Block by adrenalectomy, by RU 38486 and by bilateral lesions to the central nucleus of the amygdala. Neurochem Int 1991;20:81-92.
187. Sirinathsinghji DJS. Regulation of lordosis behaviour in the female rat by corticotropin-releasing factor, β-endorphin/corticotropin and luteinizing hormone-releasing hormone neuronal systems in the medial preoptic area. Brain Res 1986;375:49-56.
188. Skutella T, Probst JC, Criswell H, Moy C, Breese G, Jirikowski GF, Holsboer F. Antisense oligodeoxynucleotide complementary to corticotropin-releasing hormone mRNA reduces anxiety in shuttlebox performance. Neuroreport 1994a;5:2181-5.
189. Skutella T, Montkowski A, Stöhr T, Probst JC, Landgraf R, Holsboer F, Jirikowski GF. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeatinduced anxiety in rats. Cell Mol Neurobiol 1994b;14:579-88.
190. Skutella T, Probst JC, Renner R, Holsboer F, Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 1998;85:795-805.
191. Smith GW, Aubry J-M, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee K-F. Corticotropin-releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998;20:1093-102.
192. Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996;4:1-13.
193. Spengler D, Rupprecht R, Phi Van L, Holsboer F. Identification and characterization of a 3′,5′-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol 1992;6:1931-41.
194. Spina M, Merlo-Pich E, Chan RKW, Basso AM, Rivier J, Vale WW, Koob GF. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996;273:1561-4.
195. Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep 1997;20:1038-52.
196. Stenzel P, Kesterson R, Yeung W, Cone RD, Rittenberg MB, Stenzel-Poore MP. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 1995;9:637-45.
197. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992;130:3378-86.
198. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. Over-production of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 1994;14:2579-84.
199. Strijbos PJLM, Relton JK, Rothwell NJ. Corticotropin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischaemia or activation of NMDA receptors in the rat brain. Brain Res 1994;656:405-8.
200. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27:257-71.
201. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature 1982;297:331-3.
202. Swanson LW, Simmons DM. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J Comp Neurol 1989;285:413-35.
203. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983;36:165-86.
204. Swerdlow NR, Britton KT, Koob GF. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by α-helical CRF (9-41). Neuropsychopharmacology 1989;36:165-86.
205. Swiergiel AH, Takahashi LK, Kalin NH. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res 1993;623:229-34.
206. 2+ influx in cultured rat astrocytes. Biochem Biophys Res Commun 1994;1103-7.
207. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JMHM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genet 1998;19:162-6.
208. Tsai GE, Ragan P, Chang R, Chen S, Linnoila MI, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 1998;155:726-32.
209. 2 receptor for corticotropin-releasing factor. Biochem Biophys Acta 1997;1352:129-32.
210. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981;213:1394-7.
211. Valentino RJ, Wehby RG. Corticotropin-releasing factor: evidence for a neurotransmitter role in the locus coeruleus during hemodynamic stress. Neuroendocrinology 1988;48:674-7.
212. Valentino RJ, Foote SL, Aston-Jones G. Corticotropin-releasing hormone activates noradrenergic neurons of the locus coeruleus. Brain Res 1983;270:363-7.
213. Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann. NY Acad Sci 1993;697:173-88.
214. Van Bockstaele EJ, Colago EEO, Valentino RJ. Corticotropin-releasing factor-containing axon terminals synapse onto catecholemine dendrites and may presynaptically modulate other afferents in the rostral pole of the nucleus locus coeruleus in the rat brain. J Comp Neurol 1996;364:523-34.
215. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale WW. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-92.
216. Vita N, Laurent P, Lefort S, Chalon P, Lelias MJ, Kaghad M, Le Fur G, Caput D, Ferrara P. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett 1993;335:1-5.
217. von Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone-hCRH challenge in patients with depression. J Neuroendocrinol 1989;1:485-8.
218. von Bardeleben U, Holsboer F. Effect of age upon the cortisol response to human CRH in depressed patients pretreated with dexamethasone. Biol Psychiatry 1991;29:1042-50.
219. von Bardeleben U, Holsboer F, Stalla GK, Müller OA. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 1985;37:1613-18.
220. von Bardeleben U, Stalla GK, Müller OA, Holsboer F. Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pre-treatment. Biol Psychiatry 1988;24:782-6.
221. von Bardeleben U, Heuser I, Holsboer F. Human CRH stimulation response during acute withdrawal and after medium-term abstention from alcohol abuse. Psychoneuroendocrinology 1989;14:441-9.
222. Wang L. Martinez V, Vale WW, Tache Y. Peripheral injection of corticotropin-releasing factor (CRF) and a CRF-related peptide, urocortin, activate specific brain areas in rats. Gastroenterology 1996;110:A1131.
223. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. In vivo and in vitro characterization of antalarmin, a non-peptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996;137:5747-50.
224. Wiedemann K, Holsboer F. The effect of repeated human corticotropin-releasing hormone administration on dexamethasone-suppressed pituitary-adrenocortical activity in healthy subjects. Biol Psychiatry 1997;42:882-8.
225. Wiersma A, Baauw AD, Bohus B, Koohlhaas JM. Behavioural activation produced by CRH but not α-helical CRH (CRH-receptor antagonist) when microinfused into the central nucleus of the amygdala under stress-free conditions. Psychoneuroendocrinology 1995;20:423-32.
226. Wilner P. The validity of animal models of depression. Psychopharmacology 1984;83:1.
227. Wilson MA, Biscardi R, Smith MD, Wilson SP. Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: divergent responses in male and ovariectomized female rats. J Pharmacol Exp Ther 1996;278:1073-82.
228. Young EA, Akil H, Haskett RF, Watson SJ. Evidence against changes in corticotroph CRF receptors in depressed patients. Biol Psychiatry 1995;37:355-63.
229. Zobel A, Yassouridis A, Frieboes R-M, Holsboer F. Cortisol response to the combined dexamethasone-CRH test predicts medium-term outcome in patients with remitted depression. Am J Psychiatry 1999; in press.